11.07.2015 Views

Convened under the auspicious of esteemed endorsers - ISTA

Convened under the auspicious of esteemed endorsers - ISTA

Convened under the auspicious of esteemed endorsers - ISTA

SHOW MORE
SHOW LESS
  • No tags were found...

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

Concerns remain regarding <strong>the</strong> incidence <strong>of</strong> minor bleeding, consequent delayed wound healingand subsequent risk <strong>of</strong> infection. The aim <strong>of</strong> this observational study was to assess <strong>the</strong> incidence<strong>of</strong> post-operative complications in patients receiving ei<strong>the</strong>r rivaroxaban or enoxaparinthromboprophylaxis following elective hip and knee arthroplasty.Methods258 patients <strong>under</strong>going elective total hip or knee arthroplasty within one NHS Trust wereincluded. 202 subjects (mean age 70.7 years ± 10.0, 43% male) received a daily dose <strong>of</strong> 10mg<strong>of</strong> oral rivaroxaban and 56 (mean age 70.9 years ± 9.8, 39% male) had a daily subcutaneousinjection <strong>of</strong> 40 mg <strong>of</strong> enoxaparin as thromboprophylaxis. Endpoints included VTE (deep veinthrombosis and pulmonary embolism), haemorrhagic wound complications, hospital readmission,requirement for blood transfusion, minor and major bleeding and death.ResultsThere were no significant differences in <strong>the</strong> incidence <strong>of</strong> deep vein thrombosis, requirement forblood transfusion and readmission rate between rivaroxaban and enoxaparin-treated patients.However, <strong>the</strong> incidence <strong>of</strong> minor bleeding (2.0% versus 0%) and haemorrhagic woundcomplications (4.9% versus 1.8%) were non-significantly higher in <strong>the</strong> rivaroxaban-treatedgroup. There were no cases <strong>of</strong> pulmonary embolism, major bleeding or death in ei<strong>the</strong>r group.ConclusionOur experience with rivaroxaban in elective hip and knee arthroplasty showed no significantdifference in <strong>the</strong> incidence <strong>of</strong> VTE or major bleeding. There was, however, a tendency togreater risk <strong>of</strong> minor bleeding and consequent delayed wound healing affecting both morbidityand delaying discharge. These may predispose patients to a higher risk <strong>of</strong> wound infection, andthus <strong>the</strong>se issues require fur<strong>the</strong>r large scale evaluation.Rivaroxaban Group n=202 Enoxaparin Group n=56DVT/PE 2 (1.0%) 1 (1.8%)Blood Transfusion (≥ 2 units) 13 (6.4%) 4 (7.1%)Wound complications 10 (4.9%) 1 (1.8%)Minor bleeding 4 (2.0%) 0Major bleeding 0 0Readmission 2 (1.0%) 1(1.8%)Death 0 0Friday, October 8, 2010, 16:30-17:20Session A16: Computer Navigation in THAAcetabular Component Placement in THR: A New CT-Image-BasedDedicate S<strong>of</strong>tware*Attilio Speranza - Sapienza University <strong>of</strong> Rome/Sant' Andrea Hospital - Rome, Italyfile:///E|/<strong>ISTA</strong>2010-Abstracts.htm[12/7/2011 3:15:47 PM]

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!